ABVC Biopharma Files 8-K/A Amendment
Ticker: ABVC · Form: 8-K/A · Filed: May 30, 2025 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | 8-K/A |
| Filed Date | May 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, equity-sale, filing
TL;DR
ABVC Bio amended its filing on unregistered equity sales from April 30.
AI Summary
ABVC Biopharma, Inc. filed an 8-K/A on May 30, 2025, to amend a previous filing concerning unregistered sales of equity securities. The amendment relates to events that occurred on April 30, 2025. The filing does not provide specific details on the equity sold or the parties involved.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to information previously disclosed regarding equity sales, which could impact investor understanding of the company's capital structure.
Risk Assessment
Risk Level: medium — Amendments to filings, especially concerning unregistered equity sales, can signal underlying issues or complexities in the company's financial dealings.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — Registrant
- 001-40700 (company) — SEC File Number
- 26-0014658 (company) — IRS Employer Identification No.
- Nevada (company) — State of Incorporation
- April 30, 2025 (date) — Date of earliest event reported
- May 30, 2025 (date) — Date of Report
FAQ
What specific equity securities were sold in the unregistered offering?
The filing is an amendment to a previous report concerning unregistered sales of equity securities, but it does not specify the type or amount of equity securities sold.
Who were the purchasers of the unregistered equity securities?
The amendment does not disclose the identity of the purchasers of the unregistered equity securities.
What was the aggregate purchase price of the unregistered equity securities?
The filing does not provide the aggregate purchase price for the unregistered equity securities.
Why is ABVC Biopharma filing an amendment to its 8-K report?
ABVC Biopharma is filing an 8-K/A to amend a previous filing related to unregistered sales of equity securities, indicating a need to correct or supplement prior information.
What is the significance of the date April 30, 2025, in this filing?
April 30, 2025, is the date of the earliest event reported, which pertains to the unregistered sales of equity securities that the 8-K/A filing amends.
Filing Details
This Form 8-K/A (Form 8-K/A) was filed with the SEC on May 30, 2025 regarding ABVC BIOPHARMA, INC. (ABVC).